CLAIMS

1. Use of a competitive inhibitor which comprises PRO 140, any isotype of PRO 140, or a part, fragment, derivative, or conjugate of PRO 140 or a PRO 140 isotype in the manufacture of a medicament for treating a subject in need of immunomodulatory intervention, wherein the

competitive inhibitor to the CCR5 cell receptor does not itself have CCL5 agonist activity; and wherein the competitive inhibitor

is reducing CCL5 ligand and CCR5 receptor signaling in the subject.

2. The use of claim 1, wherein the competitive inhibitor is PRO 140.

3. The use of claim 1, wherein the competitive inhibitor results in increased cAMP levels in the subject.

4. The use of claim 1, wherein the competitive inhibitor reduces cell migration in the subject.

5. The use of claim 1, further comprising testing the subject to measure the immunomodulation triggered by administration of the competitive inhibitor.

6. The use of claim 1, further comprising monitoring the test subject to assess the therapeutic effectiveness of the competitive inhibitor.

7. The use of claim 1, further comprising adjusting a dose amount of the competitive inhibitor to achieve down-regulation of cell migration.

8. The use of claim 1, further comprising adjusting a dose amount of the competitive inhibitor to achieve increased cAMP levels.

9. The use of claim 1, further comprising administering a second competitive inhibitor to the CCR5 cell receptor.

10. The use of claim 2, further comprising replacing immunomodulatory intervention with maraviroc with PRO 140.

11. The use of claim 2, further comprising supplementing immunomodulatory intervention with maraviroc with PRO 140.

12. The use of claim 1, further comprising treating a subject with one of graft versus host disease, autoimmune disorders such as Multiple Sclerosis, Lupus, psoriasis, liver disease, Crohn's Disease, and inflammatory bowel disease, infectious agents, chronic inflammation, and cancer such as breast cancer and prostate cancer.

13. The use of claim 1, further comprising preventing the development or progression of, in a subject, one of graft versus host disease, autoimmune disorders such as Multiple Sclerosis, Lupus, psoriasis, liver disease, Crohn's Disease, and inflammatory bowel disease, infectious agents, chronic inflammation, and cancer such as breast cancer and prostate cancer.

14. The use of claim 1, further comprising reducing the inflammation of a subject with one of graft versus host disease, autoimmune disorders such as Multiple Sclerosis, Lupus, psoriasis, liver disease, Crohn's Disease, and inflammatory bowel disease, infectious agents, chronic inflammation, and cancer such as breast cancer and prostate cancer.

15. Use of a CCR5 cell receptor competitive inhibitor wherein the competitive inhibitor comprises PRO 140, any isotype of PRO 140, or a part, fragment, derivative, or conjugate of PRO 140 or a PRO 140 isotype in the manufacture of a medicament for treating a subject

wherein the competitive inhibitor inhibits CCL5 ligand bound to CCR5 receptor activity; and is

measurably reducing the immunomodulatory downstream effects of the CCL5 ligand bound to CCR5 receptor activity; and wherein the competitive inhibitor is for

treating inflammation associated with one of graft versus host disease, autoimmune disorders such as Multiple Sclerosis, Lupus, psoriasis, liver disease, Crohn's Disease, and inflammatory bowel disease, infectious agents, chronic inflammation, and cancer such as breast cancer and prostate cancer.

16. The use of claim 15, wherein the competitive inhibitor is PRO 140.

17. The use of claim 15, wherein the competitive inhibitor results in increased cAMP levels in the subject.

18. The use of claim 15, wherein the competitive inhibitor reduces cell migration in the subject.

19. The use of claim 15, further comprising monitoring the test subject to assess the therapeutic effectiveness of the competitive inhibitor.

20. The use of claim 15, further comprising adjusting a dose amount of the competitive inhibitor to achieve down-regulation of cell migration.

21. The use of claim 15, further comprising adjusting a dose amount of the competitive inhibitor to achieve increased cAMP levels.

22. The use of claim 15, further comprising replacing immunomodulatory intervention with maraviroc with PRO 140.

23. The use of claim 15, further comprising supplementing immunomodulatory intervention with maraviroc with PRO 140.

24. The use of claim 15, further comprising that a second competitive inhibitor to the CCR5 cell receptor is to be administered.

25. The use of claim 15, for treating inflammation associated with graft versus host disease.

26. The use of claim 15, for treating inflammation associated with autoimmune disorders such as Multiple Sclerosis, Lupus, psoriasis, liver disease, Crohn's Disease and inflammatory bowel disease.

27. The use of claim 15, for treating inflammation associated with infectious agents.

28. The use of claim 15, for treating inflammation associated with chronic inflammation.

29. The use of claim 15, for treating inflammation associated with cancer such as breast cancer and prostate cancer